Sentynl Therapeutics, Inc.
Solana Beach
About Sentynl Therapeutics, Inc.
Sentynl Therapeutics is a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases. The company was acquired by the Zydus Group in 2017. Sentynl’s experienced management team has previously built multiple successful pharmaceutical companies. With a focus on commercialization, Sentynl looks to source effective and well-differentiated products across a broad spectrum of therapeutic areas to address unmet needs. Sentynl is committed to the highest ethical standards and compliance with all applicable laws, regulations and industry guidelines. For more information, visit https://sentynl.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Website: sentynl.com
- Phone: 888-507-5206
Industries & Categories
Biopharma, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sentynl-therapeutics-inc-204788 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.